🇺🇸 FDA

Company profile · Sponsor

Incyte

Incyte Biosciences Distribution B.V.

E5F69C6 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Incyte (E5F69C6) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E5F69C6
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. Axatilimab (INCA034176)

    Incyte

    Chronic Graft-Versus-Host Disease

    phase 3 small molecule active

    1 trial

  2. INCA33890, Placebo contains the same formulation buffer, 10 mM acetate, 9% (w/v) sucrose and 0.02% (w/v) polysorbate 80, at pH 5.5, without the active pharmaceutical ingredient., CALCIUM FOLINATE, BEVACIZUMAB, OXALIPLATIN, FLUOROURACIL

    Incyte

    Metastatic Microsatellite Stable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Epacadostat, CETUXIMAB , Epacadostat, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , FLUOROURACIL

    Incyte

    Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies

    phase 3 small molecule active

    1 trial

  4. METHYLPREDNISOLONE, Axatilimab (INCA034176), Placebo, PREDNISONE

    Incyte

    chronic graft-versus-host disease

    phase 3 small molecule active

    1 trial

  5. MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia

    phase 3 small molecule active

    1 trial

  6. PACLITAXEL, TOPOTECAN HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion

    Incyte

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  7. Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung

    Incyte

    Metastatic nonsquamous or squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  8. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  9. Placebo to Povorcitinib, Povorcitinib

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  10. Placebo to Povorcitinib, Povorcitinib, Povorcitinib

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  11. Povorcitinib, Placebo to Povorcitinib

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  12. Povorcitinib, Placebo to Povorcitinib, Povorcitinib

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  13. Povorcitinib, Povorcitinib

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  14. Povorcitinib, Povorcitinib, Povorcitinib

    Incyte

    Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo

    phase 3 small molecule active

    1 trial

  15. RITUXIMAB , SODIUM CHLORIDE, Placebo for lenalidomide 25mg, PREDNISONE , MINJUVI 200 mg powder for concentrate for solution for infusion, PREDNISOLONE , LENALIDOMIDE, DOXORUBICIN , Placebo for lenalidomide 10mg, VINCRISTINE , LENALIDOMIDE, Placebo for lenalidomide 15mg, LENALIDOMIDE, CYCLOPHOSPHAMIDE

    Incyte

    Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  16. Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)

    Incyte

    Squamous Carcinoma of the Anal Canal

    phase 3 small molecule active

    1 trial

  17. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  18. Ruxolitinib (INCB018424) cream, Ruxolitinib (INCB018424) cream, Vehicle (placebo) cream

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  19. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  20. Sutent 12.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PAZOPANIB , Sutent 25 mg hard capsules

    Incyte

    Locally advanced/metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  21. Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid), Ruxolitinib (INCB018424) cream

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  22. Vehicle cream (same formulation of cream as the test product but without active substance), Ruxolitinib (INCB018424) cream

    Incyte

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  23. Vehicle cream: same formulation of cream as the test product but without active substance and phosphoric acid, Ruxolitinib (INCB018424) cream

    Incyte

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  24. Vehicle cream: same formulation of cream as the test product but without active substance., Ruxolitinib (INCB018424) cream

    Incyte

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Incyte?

Incyte (E5F69C6) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Incyte sponsor?

We track 24 ClinicalTrials.gov-linked programs for Incyte, including Axatilimab (INCA034176) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Incyte company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.